Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 21.00 141,915 08:00:00
Bid Price Offer Price High Price Low Price Open Price
20.00 22.00 21.00 21.00 21.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.11 5.04 9.16 2.3 71
Last Trade Time Trade Type Trade Size Trade Price Currency
16:26:32 O 1,159 20.251 GBX

Summit Therapeutics (SUMM) Latest News

More Summit Therapeutics News
Summit Therapeutics Takeover Rumours

Summit Therapeutics (SUMM) Discussions and Chat

Summit Therapeutics (SUMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Summit Therapeutics trades in real-time

Summit Therapeutics (SUMM) Top Chat Posts

DateSubject
19/1/2020
08:20
Summit Therapeutics Daily Update: Summit Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Therapeutics was 21p.
Summit Therapeutics Plc has a 4 week average price of 19.50p and a 12 week average price of 19.50p.
The 1 year high share price is 34p while the 1 year low share price is currently 18.50p.
There are currently 335,873,208 shares in issue and the average daily traded volume is 205,087 shares. The market capitalisation of Summit Therapeutics Plc is £70,533,373.68.
09/12/2019
17:54
hernando2: So Duggan is in for 70 odd million ( i think), 28% of shares out of his hands,,so quite illiquid sometime in the next 12 months the share price shoots up, driven by aggressive buying by persons unknown. Due to lack of liquidity, Duggan reluctantly releases 25% of his holding into the market, selling in tranches to satisfy demand. Reducing significantly his financial exposure but still giving him most of the company should things go well, minimal loss if things go badly. Just another take on the situaltion I bought Friday at 19 and 20.
06/12/2019
20:15
someuwin: The US ADRs (American Depositary Receipt) can't exist on their own, they're just a proxy for the UK AIM shares. If they cancel the AIM listing but want to keep the US listing they'll have to convert the existing shares to full status US shares. Thus all our shares will automatically convert over (and can be held in ISA's and SIPPs as normal - I have loads of APPL, GOOGL, FB etc in these accounts). This in itself should significantly boost the share price. I've noticed with other stocks that although normally Nasdaq rates tech / pharma stocks on much higher ratings, if a stock is dual listed with AIM then the AIM market will act as a drag constantly pulling the valuation down. All in all, today's news looks transformational to me.
21/10/2019
15:29
kirk 6: Yes you keep saying I disagree if the market over on the pond has a deal we shoulda be watching the Nasdaq for volume and share price Nice volume today aswell
21/10/2019
11:04
wildbunch: Read my earlier posts-big minority shareholder will not let this go-low share price makes buy out cheaper. This has nothing to do with NASDAQ or AIM-all to do with whether BOD get alternative financing PDQ-or do they really want to do so? Time for people to wake up and smell the coffee. Thats' all.
18/10/2019
16:59
kirk 6: Looking for share price movements indicating a potential finance deal. Happened last time.U.K. normally follows Nasdaq
16/10/2019
09:53
wildbunch: What am I missing here? Funding is sorted it-the large minority shareholder will not let this fold so will stump up the cash if necessary-but on what terms. Buy out at then existing share price plus x% premium. A couple of years down the line it may be worth say £1bn and we won't have seen much of that. Remember, he knew when he took his stake that Summit were going to run out of money way before Phase 3 tests were over-so this 'crisis' was predictable. I am sure the CEO et al will be fine-look at how they dumped their previous shoe options and were immediately awarded with more at a much lower exercise price to 'motivate' them. This may seem cynical-but the facts fit. Hope we get alternative source of funding which keeps us in the game. GLA
24/9/2019
11:48
kirk 6: So much good news after good news after good news yet share price virtually all time lowLet's hope we get some bad news soon
14/3/2019
11:06
football: Summit Therapeutics plc Summit Highlights Use Of Discuva Platform In Identifying New Mechanism Antibiotics Against Neisseria ... Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference -- N. Gonorrhoeae and ESKAPE Pathogens Identified as High Priority by the US CDC and the WHO https://uk.advfn.com/stock-market/london/summit-corp-SUMM/share-news/Summit-Therapeutics-plc-Summit-Highlights-Use-Of-D/79470756
19/12/2018
07:58
waterloo01: Thanks for that. Summit Therapeutics (SUMM) What have shares done? Summit has not had a good year. Shares fell off a cliff in June from 195p to 36.9p. They have recovered slightly to sit at 20.3p. What’s its current market cap? £14.8m. What was cash at last count? The company had cash and cash equivalents of £13m on 31 October 2018. However, earlier this week it announced that it would raise $25m by selling American Depositary Shares in a private placement. What’s next? As we have noted before, the biotech firm fell by as much as 80pc in July. This came after it revealed that it had discontinued its treatment for Duchenne Muscular Dystrophy. Despite this setback, the firm has been working to move forward. It is now focusing on the development of the three antibiotics left in its pipeline. This week, the business announced a whopping $25m placing. The funds will support a critical phase three clinical programme for ridinilazole. This is an antibiotic for colon infection C. Difficile. Unlike similar medications, it does not cause damage to natural gut flora during treatment. The money will also advance studies for the treatment of gonorrhoea. As Summit has demonstrated, investing in pharma businesses can be a bit like roulette. This is because these businesses often completely hang on the outcome of trials and the whim of regulators. If this is of interest, then Summit’s ambitious work programme could generate some significant share price movement.
21/5/2018
12:27
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
Summit Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200120 06:01:40